BioLineRx Scheduled to Announce Q1 Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 55 minutes ago
0mins
Source: seekingalpha
- Earnings Announcement Date: BioLineRx (BLRX) is set to announce its Q1 2023 earnings on May 27 before the market opens, drawing significant attention from investors regarding its performance.
- Earnings Expectations: The consensus EPS estimate stands at -$1.04, with revenue expected to reach $0.34 million, reflecting a 30.8% year-over-year growth, indicating potential for revenue growth.
- Historical Performance Review: Over the past year, BioLineRx has beaten EPS estimates 25% of the time and revenue estimates 75% of the time, demonstrating a degree of stability in its financial performance.
- Expectation Revision Status: In the last three months, there have been no upward revisions for EPS or revenue estimates, with one downward revision each, suggesting a cautious market outlook on the company's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BLRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BLRX
Wall Street analysts forecast BLRX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.060
Low
12.00
Averages
12.00
High
12.00
Current: 3.060
Low
12.00
Averages
12.00
High
12.00
No data
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioLineRx Scheduled to Announce Q1 Earnings
- Earnings Announcement Date: BioLineRx (BLRX) is set to announce its Q1 2023 earnings on May 27 before the market opens, drawing significant attention from investors regarding its performance.
- Earnings Expectations: The consensus EPS estimate stands at -$1.04, with revenue expected to reach $0.34 million, reflecting a 30.8% year-over-year growth, indicating potential for revenue growth.
- Historical Performance Review: Over the past year, BioLineRx has beaten EPS estimates 25% of the time and revenue estimates 75% of the time, demonstrating a degree of stability in its financial performance.
- Expectation Revision Status: In the last three months, there have been no upward revisions for EPS or revenue estimates, with one downward revision each, suggesting a cautious market outlook on the company's future performance.
See More
BioLineRx and Hemispherian to Present GLIX1 Abstracts at ASCO 2026
- Research Presentation: BioLineRx and Hemispherian announced the publication of two abstracts featuring GLIX1 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing their latest advancements in oncology, which is expected to attract significant industry attention.
- Conference Details: The ASCO Annual Meeting will take place from May 29 to June 2, 2026, in Chicago, Illinois, bringing together leading oncology experts and researchers from around the world, providing a crucial platform for academic exchange and collaboration.
- Clinical Stage Progress: As a clinical-stage biopharmaceutical company focused on developing life-changing therapies for oncology and rare diseases, the presentation of these research findings will further enhance BioLineRx's influence and market recognition within the industry.
- Strategic Collaboration Significance: The partnership with Hemispherian not only demonstrates a shared vision in oncology treatment but may also lay the groundwork for future joint research and market promotion, advancing the clinical application of new therapies.
See More
BioLineRx and Hemispherian Present GLIX1 Research Findings
- Clinical Trial Initiation: BioLineRx initiated the Phase 1 clinical trial of GLIX1 in March 2026, targeting glioblastoma (GBM) by inducing tumor-selective DNA strand breaks through TET2 activity restoration, indicating potential applications across various cancers.
- ASCO Conference Presentation: Two abstracts on GLIX1 will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting its potential as a monotherapy and synergistic effects when combined with PARP inhibitors, which could provide new strategies for cancer treatment.
- Innovative Drug Mechanism: GLIX1 enhances TET2 activity, promoting DNA demethylation and leading to the accumulation of single-strand DNA breaks that convert into lethal double-strand breaks in cancer cells, with preclinical studies demonstrating strong antitumor activity across multiple cancer cell lines.
- Safety Study Results: Animal safety studies indicate that GLIX1 is well-tolerated at the highest tested doses (2000mg/kg), and in mice, oral dosing achieves brain exposure levels corresponding to 68-85% of plasma concentrations, laying a solid foundation for its clinical application.
See More
BioLineRx and Hemispherian Present New GLIX1 Data
- Clinical Trial Progress: BioLineRx initiated the first-in-human Phase 1/2a clinical trial of GLIX1 in March 2026, targeting glioblastoma (GBM) by restoring TET2 activity to induce tumor-selective DNA breaks, showcasing potential applications across various cancers.
- ASCO Conference Presentation: Two abstracts on GLIX1 will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting its potential as a monotherapy and in combination with PARP inhibitors, which may introduce new strategies in cancer treatment.
- Innovative Drug Mechanism: GLIX1 enhances TET2 activity, promoting DNA demethylation and leading to single-strand DNA breaks that convert into lethal double-strand breaks, particularly relevant for GBM patients with significantly impaired TET2 activity, underscoring its clinical significance.
- Safety Study Results: Animal safety studies indicate that GLIX1 is well-tolerated at maximum doses of 2000mg/kg in rats and 1000mg/kg in dogs, supporting its safety profile for clinical use and laying the groundwork for future clinical development.
See More
BioLineRx to Release Q1 Financial Results on May 27
- Earnings Release Schedule: BioLineRx plans to announce its unaudited financial results for the quarter ending March 31, 2026, on May 27, 2026, before U.S. market open, indicating ongoing progress in the clinical-stage biopharmaceutical sector.
- Conference Call Details: The company will host a conference call at 8:30 a.m. EDT, featuring remarks from CEO Philip Serlin, expected to discuss financial results and future strategies, thereby enhancing investor confidence in the company's outlook.
- GLIX1 Clinical Progress: BioLineRx's lead development asset, GLIX1, has initiated a Phase 1/2a clinical trial in Q1 2026 targeting glioblastoma and other solid tumors, showcasing the company's innovative potential in cancer treatment.
- Product Commercialization Status: The company's first approved product, APHEXDA®, is being commercialized globally, except in Asia where Ayrmid Ltd. and Gloria Biosciences are responsible, indicating BioLineRx's capability for global market expansion.
See More
New Preclinical Data Enhances GLIX1 Efficacy
- Efficacy Validation: New preclinical data demonstrate GLIX1's robust anti-tumor activity in a dose-dependent manner, showing effectiveness even at the lowest doses tested, indicating its potential in treating recurrent and progressive GBM.
- Clinical Trial Progress: BioLineRx and Hemispherian AS announced the initiation of a Phase 1/2a clinical trial for GLIX1, aimed at evaluating its efficacy against high-grade gliomas, marking a significant advancement in oncology treatment.
- Market Demand: The development of GLIX1 addresses a high unmet medical need, particularly among GBM patients, suggesting substantial market opportunities upon successful commercialization to meet the urgent demand for new therapies.
- Collaborative Outlook: The partnership between BioLineRx and Hemispherian AS not only enhances their research capabilities in oncology but may also accelerate GLIX1's market introduction, strengthening the companies' competitive position in the biopharmaceutical industry.
See More
BioLineRx Scheduled to Announce Q1 Earnings
- Earnings Announcement Date: BioLineRx (BLRX) is set to announce its Q1 2023 earnings on May 27 before the market opens, drawing significant attention from investors regarding its performance.
- Earnings Expectations: The consensus EPS estimate stands at -$1.04, with revenue expected to reach $0.34 million, reflecting a 30.8% year-over-year growth, indicating potential for revenue growth.
- Historical Performance Review: Over the past year, BioLineRx has beaten EPS estimates 25% of the time and revenue estimates 75% of the time, demonstrating a degree of stability in its financial performance.
- Expectation Revision Status: In the last three months, there have been no upward revisions for EPS or revenue estimates, with one downward revision each, suggesting a cautious market outlook on the company's future performance.
See More
BioLineRx and Hemispherian to Present GLIX1 Abstracts at ASCO 2026
- Research Presentation: BioLineRx and Hemispherian announced the publication of two abstracts featuring GLIX1 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing their latest advancements in oncology, which is expected to attract significant industry attention.
- Conference Details: The ASCO Annual Meeting will take place from May 29 to June 2, 2026, in Chicago, Illinois, bringing together leading oncology experts and researchers from around the world, providing a crucial platform for academic exchange and collaboration.
- Clinical Stage Progress: As a clinical-stage biopharmaceutical company focused on developing life-changing therapies for oncology and rare diseases, the presentation of these research findings will further enhance BioLineRx's influence and market recognition within the industry.
- Strategic Collaboration Significance: The partnership with Hemispherian not only demonstrates a shared vision in oncology treatment but may also lay the groundwork for future joint research and market promotion, advancing the clinical application of new therapies.
See More
BioLineRx and Hemispherian Present GLIX1 Research Findings
- Clinical Trial Initiation: BioLineRx initiated the Phase 1 clinical trial of GLIX1 in March 2026, targeting glioblastoma (GBM) by inducing tumor-selective DNA strand breaks through TET2 activity restoration, indicating potential applications across various cancers.
- ASCO Conference Presentation: Two abstracts on GLIX1 will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting its potential as a monotherapy and synergistic effects when combined with PARP inhibitors, which could provide new strategies for cancer treatment.
- Innovative Drug Mechanism: GLIX1 enhances TET2 activity, promoting DNA demethylation and leading to the accumulation of single-strand DNA breaks that convert into lethal double-strand breaks in cancer cells, with preclinical studies demonstrating strong antitumor activity across multiple cancer cell lines.
- Safety Study Results: Animal safety studies indicate that GLIX1 is well-tolerated at the highest tested doses (2000mg/kg), and in mice, oral dosing achieves brain exposure levels corresponding to 68-85% of plasma concentrations, laying a solid foundation for its clinical application.
See More
BioLineRx and Hemispherian Present New GLIX1 Data
- Clinical Trial Progress: BioLineRx initiated the first-in-human Phase 1/2a clinical trial of GLIX1 in March 2026, targeting glioblastoma (GBM) by restoring TET2 activity to induce tumor-selective DNA breaks, showcasing potential applications across various cancers.
- ASCO Conference Presentation: Two abstracts on GLIX1 will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting its potential as a monotherapy and in combination with PARP inhibitors, which may introduce new strategies in cancer treatment.
- Innovative Drug Mechanism: GLIX1 enhances TET2 activity, promoting DNA demethylation and leading to single-strand DNA breaks that convert into lethal double-strand breaks, particularly relevant for GBM patients with significantly impaired TET2 activity, underscoring its clinical significance.
- Safety Study Results: Animal safety studies indicate that GLIX1 is well-tolerated at maximum doses of 2000mg/kg in rats and 1000mg/kg in dogs, supporting its safety profile for clinical use and laying the groundwork for future clinical development.
See More
BioLineRx to Release Q1 Financial Results on May 27
- Earnings Release Schedule: BioLineRx plans to announce its unaudited financial results for the quarter ending March 31, 2026, on May 27, 2026, before U.S. market open, indicating ongoing progress in the clinical-stage biopharmaceutical sector.
- Conference Call Details: The company will host a conference call at 8:30 a.m. EDT, featuring remarks from CEO Philip Serlin, expected to discuss financial results and future strategies, thereby enhancing investor confidence in the company's outlook.
- GLIX1 Clinical Progress: BioLineRx's lead development asset, GLIX1, has initiated a Phase 1/2a clinical trial in Q1 2026 targeting glioblastoma and other solid tumors, showcasing the company's innovative potential in cancer treatment.
- Product Commercialization Status: The company's first approved product, APHEXDA®, is being commercialized globally, except in Asia where Ayrmid Ltd. and Gloria Biosciences are responsible, indicating BioLineRx's capability for global market expansion.
See More
New Preclinical Data Enhances GLIX1 Efficacy
- Efficacy Validation: New preclinical data demonstrate GLIX1's robust anti-tumor activity in a dose-dependent manner, showing effectiveness even at the lowest doses tested, indicating its potential in treating recurrent and progressive GBM.
- Clinical Trial Progress: BioLineRx and Hemispherian AS announced the initiation of a Phase 1/2a clinical trial for GLIX1, aimed at evaluating its efficacy against high-grade gliomas, marking a significant advancement in oncology treatment.
- Market Demand: The development of GLIX1 addresses a high unmet medical need, particularly among GBM patients, suggesting substantial market opportunities upon successful commercialization to meet the urgent demand for new therapies.
- Collaborative Outlook: The partnership between BioLineRx and Hemispherian AS not only enhances their research capabilities in oncology but may also accelerate GLIX1's market introduction, strengthening the companies' competitive position in the biopharmaceutical industry.
See More
